News: Camrus CAM2029 Octreotide FluidCrystal
“Lund, Sweden. 26 May, 2009 – Camurus announced today that the European Medicines Agency’s (EMEA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on the application for orphan designation for Camurus’ drug product CAM2029 (octreotide chloride FluidCrystal® Injection depot) for treatment of acromegaly.”
Exciting news – because this drug is a once-a-month drug administered as a subcutaneaous injection using a small thin needle (just under the skin) as opposed to current long-acting preparations of octreotide that need to be administered into muscle tissue. As a result the drug will be straightforward for the patient to administer themselves.